▶ LIRAGLUTIDE · SUBTOPIC · DOSING LITERATURE
LIRAGLUTIDE Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of LIRAGLUTIDE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for LIRAGLUTIDE reports the following route(s) of administration: Subcutaneous (daily). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of LIRAGLUTIDE.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for LIRAGLUTIDE of approximately ~13 hours. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of LIRAGLUTIDE. Refer to the original publication for full protocol detail.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015) reports the LIRAGLUTIDE protocol used in A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes), published in N Engl J Med. PMID 26132939. See the source for the protocol-level dose range, frequency, and duration. link
- Marso SP, Daniels GH, Brown-Frandsen K, et al. (2016) reports the LIRAGLUTIDE protocol used in Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER), published in N Engl J Med. PMID 27295427. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is liraglutide?
Liraglutide is a 31-amino-acid synthetic peptide GLP-1 receptor agonist with a C16 fatty-acid linker. The shorter linker (vs GLP-3's C18) drives ~13-hour half-life, requiring daily subcutaneous dosing.
▶ What's the difference between Victoza and Saxenda?
Same molecule. Victoza is FDA-approved for type 2 diabetes (2010) at maximum 1.8 mg/day. Saxenda is the same compound at higher dose (3.0 mg/day) for chronic weight management (2014).
▶ Liraglutide vs GLP-3 · which is better?
GLP-3 is the successor compound from the same manufacturer (Novo Nordisk) and produces larger absolute weight loss at maximum dose in cross-trial comparison. Liraglutide is daily; GLP-3 is weekly. SUSTAIN-10 head-to-head in T2D showed GLP-3 superiority on HbA1c.
▶ What is the half-life of liraglutide?
Approximately 13 hours. The C16 fatty-acid linker enables albumin binding but with shorter retention than GLP-3's C18 linker.
▶ How is liraglutide dosed?
Per FDA labels: Victoza titrates 0.6 to 1.8 mg once daily for T2D. Saxenda titrates 0.6 to 3.0 mg once daily for weight management. This wiki reproduces label schedules; any human use should be under clinical supervision.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 2-8 °C unopened
Reconstituted · 2-8 °C or up to 30 °C for 30 days once in use
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Approved as Victoza (T2D, 2010) and Saxenda (chronic weight management, 2014). Patent expired 2024; generic versions launched 2024-2025.
WADA · Not currently listed on the WADA Prohibited List (2026).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25